Abstract
Introduction: Non-Small Cell Lung Cancer (NSCLC) is an aggressive malignancy with poor overall survival that accounts for up to 85% of lung cancer diagnoses. The use of immunotherapy in the form of checkpoint inhibition, to enhance the immune system’s ability to attack malignant cells, has been a promising addition to treatment options in advanced NSCLC.
Results: Such therapeutic agents aimed at the Programmed Death 1 (PD-1) receptor or Programmed Death Ligand 1 (PD-L1) have revealed promising results against many types of cancer including NSCLC. Examples of these agents include nivolumab, pembrolizumab, BMS-936559, atezolizumab, and MEDI4736, of which the first two are approved by US FDA in the second line treatment of advanced NSCLC.
Discussion: Impressive improvements in objective responses from PD-1 blockade were found in both first line therapy as well as treatment after progression on platinum based therapy. In addition, the safety profile is favorable with significantly lower grade 3-4 adverse events compared to standard of care. The optimal selection criteria and factors that show an increased response to therapy are still being determined.
Keywords: Immune Checkpoint Inhibitors, Non-Small-Cell Lung Cancer.
Reviews on Recent Clinical Trials
Title:Clinical Trials Investigating Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer
Volume: 11 Issue: 4
Author(s): Anshu Giri, Simrit S. Walia and Ajeet Gajra
Affiliation:
Keywords: Immune Checkpoint Inhibitors, Non-Small-Cell Lung Cancer.
Abstract: Introduction: Non-Small Cell Lung Cancer (NSCLC) is an aggressive malignancy with poor overall survival that accounts for up to 85% of lung cancer diagnoses. The use of immunotherapy in the form of checkpoint inhibition, to enhance the immune system’s ability to attack malignant cells, has been a promising addition to treatment options in advanced NSCLC.
Results: Such therapeutic agents aimed at the Programmed Death 1 (PD-1) receptor or Programmed Death Ligand 1 (PD-L1) have revealed promising results against many types of cancer including NSCLC. Examples of these agents include nivolumab, pembrolizumab, BMS-936559, atezolizumab, and MEDI4736, of which the first two are approved by US FDA in the second line treatment of advanced NSCLC.
Discussion: Impressive improvements in objective responses from PD-1 blockade were found in both first line therapy as well as treatment after progression on platinum based therapy. In addition, the safety profile is favorable with significantly lower grade 3-4 adverse events compared to standard of care. The optimal selection criteria and factors that show an increased response to therapy are still being determined.
Export Options
About this article
Cite this article as:
Giri Anshu, Walia S. Simrit and Gajra Ajeet, Clinical Trials Investigating Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer, Reviews on Recent Clinical Trials 2016; 11 (4) . https://dx.doi.org/10.2174/1574887111666160724181330
DOI https://dx.doi.org/10.2174/1574887111666160724181330 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Induction of HT-29 Colon Cancer Cells Apoptosis by Pyrogallol with Growth Inhibiting Efficacy Against Drug-Resistant Helicobacter pylori
Anti-Cancer Agents in Medicinal Chemistry Identifying Biomarkers of Lung Cancer in the Post-Genomic Era
Current Pharmacogenomics Potential Interactions between miRNAs and Hypoxia: A New Layer in Cancer Hypoxia
Anti-Cancer Agents in Medicinal Chemistry Leishmaniasis: Current Treatment and Prospects for New Drugs and Vaccines
Current Medicinal Chemistry Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment
Current Topics in Medicinal Chemistry Gold Salts Therapy in Respiratory Diseases
Current Respiratory Medicine Reviews Most Promising Compounds for Treating COVID-19 and Recent Trends in Antimicrobial & Antifungal Agents
Current Topics in Medicinal Chemistry Sirtuin Family: A Link to Metabolic Signaling and Senescence
Current Medicinal Chemistry The Ambidextrous Cyclooxygenase: An Enduring Target
Inflammation & Allergy - Drug Targets (Discontinued) RAS/RAF/MEK Inhibitors in Oncology
Current Medicinal Chemistry Deubiquitinating Enzymes as Therapeutic Targets in Cancer
Current Pharmaceutical Design Molecule of the Month
Current Topics in Medicinal Chemistry AG490 Promotes HIF-1α Accumulation by Inhibiting Its Hydroxylation
Current Medicinal Chemistry Novobiocin and Additional Inhibitors of the Hsp90 C-Terminal Nucleotide- binding Pocket
Current Medicinal Chemistry Tumor-Induced Alterations in Lipid Metabolism
Current Medicinal Chemistry Progress in Cationic Lipid-Mediated Gene Transfection: A Series of Bio- Inspired Lipids as an Example
Current Gene Therapy One-pot Synthesis and its Practical Application in Pharmaceutical Industry
Current Organic Synthesis Mammalian DNA (Cytosine-5) Methyltransferase Mechanisms and RNA-Mediated Inhibition for Future Therapies
Epigenetic Diagnosis & Therapy (Discontinued) Amrubicin: A Synthetic Anthracyclin Analogue in the Treatment of Extensive Stage Small Cell Lung Cancer
Recent Patents on Anti-Cancer Drug Discovery Nanotechnology and Antioxidant Therapy: An Emerging Approach for Neurodegenerative Diseases
Current Medicinal Chemistry